Literature DB >> 30292418

Multidisciplinary treatment of lung cancer in older patients: A review.

Marco Radovic1, Ravindran Kanesvaran2, Achim Rittmeyer3, Martin Früh4, Fabrizio Minervini5, Markus Glatzer1, Paul Martin Putora6.   

Abstract

Lung cancer is the leading cause of cancer death worldwide. Older patients represent approximately half of the patient population and optimal management of these patients is challenging. In early-stagenon-small cell lung cancer (NSCLC), lobectomy should be considered in fit older patients. For unfit patients, stereotactic body radiotherapy (SBRT) represents a good alternative. While data on the benefit and risk of concurrent chemo-radiotherapy (cCRT) in older patients with locally advanced NSCLC is conflicting, age alone should not preclude cCRT. Multidisciplinary collaboration is essential for appropriate patient selection. In limited disease small cell lung cancer (SCLC), older patients appear to benefit similarly from standard treatment compared to their younger counterparts, however, with a higher risk of toxicity. Appropriately selected older patients with lung cancer seem to derive as much benefit from active oncological treatment as their younger counterparts. Geriatric screening tests and comprehensive geriatric assessments (CGA) can be helpful when choosing between treatment strategies. Older patients are at risk for under-treatment; this should be avoided by proper selection and multidisciplinary management. This review outlines the management of lung cancer in older patients.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Year:  2018        PMID: 30292418     DOI: 10.1016/j.jgo.2018.09.005

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  5 in total

1.  Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4-mediated ferroptosis.

Authors:  Xiaofen Pan; Zhixiu Lin; Danxian Jiang; Ying Yu; Donghong Yang; Hechao Zhou; Dechao Zhan; Sha Liu; Gang Peng; Zihong Chen; Zhonghua Yu
Journal:  Oncol Lett       Date:  2019-01-04       Impact factor: 2.967

2.  LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.

Authors:  Wenlong He; Yeying Zhang; Shulan Xia
Journal:  Thorac Cancer       Date:  2020-01-10       Impact factor: 3.500

Review 3.  Ferroptosis: A New Promising Target for Lung Cancer Therapy.

Authors:  Rui Xiong; Ruyuan He; Bohao Liu; Wenyang Jiang; Bo Wang; Ning Li; Qing Geng
Journal:  Oxid Med Cell Longev       Date:  2021-09-25       Impact factor: 6.543

4.  Hsa_circ_0006427 Suppresses Multiplication, Migration and Invasion of Non-Small Cell Lung Cancer Cells through miR-346/VGLL4 Pathway.

Authors:  Jia Cheng Sun; Lei Wang; Xin Hai Zhu; Mo Lei Shen
Journal:  Cell J       Date:  2022-04-27       Impact factor: 3.128

5.  Effect of Pressure-Controlled Ventilation-Volume Guaranteed on One-Lung Ventilation in Elderly Patients Undergoing Thoracotomy.

Authors:  Wenyu Yao; Mingyuan Yang; Qinghao Cheng; Shiqiang Shan; Bo Yang; Qian Han; Jun Ma
Journal:  Med Sci Monit       Date:  2020-02-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.